Yes I agree, also they have already had a sample of Amarex's work product... But something has changed; another biotech company also recently completed a clinical trial and filed to the SEC for an IPO. Buried in the 200 page filing was a reference to OWS requesting un blinded data from 25 patients and blending with the open label results and employing their own (OWS) statistics, which produced p-values below .0001, yet the company did not announce this publically??